Research Reviews
TB-500 Half-Life and Mechanism: What Is Documented
No formal half-life study exists for TB-500's heptapeptide. What metabolite work shows, how the actin-binding region is thought to act, and how to read claims.
Pharmacokinetics
Half-life, clearance, distribution, and the engineering that changes them: albumin binding, fatty-acid conjugation, PEGylation and backbone modification. Every figure is reported with the species and the study it came from.
Research Reviews
Tirzepatide Half-Life: About Five Days, and Why
Tirzepatide's half-life is about 5 days, from a population PK model of 19 pooled studies. How albumin binding produces it and what it means for study design.
Research Reviews
Kisspeptin-10 Half-Life and Its Decomposition Product
A 2013 LC-MS/MS study measured kisspeptin-10 pharmacokinetics in rats and characterised its decomposition product. What that means for handling.
Research Reviews
IGF-1 LR3 Half-Life and What Receptor Grade Means
IGF-1 LR3's persistence comes from evading binding proteins, not from intrinsic stability. What the clearance literature shows and what grade labels mean.
Research Reviews
Retatrutide Half-Life: What Phase 1 Data Show
Retatrutide's half-life in humans is about 6 days in a phase 1b trial. How it was measured, why it is so long, and what it means for stability.
Research Reviews
BPC-157 Half-Life: What Published Studies Report
BPC-157's plasma half-life is under 30 minutes in rats and dogs. What the PK study measured, how the peptide is cleared, and what it means in the lab.